Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

“…Moreover, the success of mobilization could not be distinguished by differences in baseline full blood counts (data not shown). These findings extend and confirm the results from two recent studies with data from the US plerixafor CUP for mobilization failures, one coming from a Genzyme Corporation-led data audit of the US CUP, 20 and the other one from a single-center experience, 21 which showed success rates for this combination from 66 to 85%, respectively.…”

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

“…Other authors have reported similar success rates in patients who failed previous mobilization attempts: Tricot et al 25 examined the use of plerixafor in 10 proven and 10 predicted poor mobilizers diagnosed with MM and reported a success rate of 85% in this openlabeled single-center study, whereas Micallef et al 26 reported 63.5% success in the remobilization of 298 NHL patients in a randomized controlled prospective phase III study. Fowler et al 27 reported an overall success rate of 85% with plerixafor in just one apheresis session in 20 patients who failed a previous standard cytokine-assisted mobilization attempt. In this report, all patients diagnosed with NHL, as well as MM, yielded sufficient cells to undergo high-dose chemotherapy and transplantation.…”

Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience

“…[32][33][34][35] In addition, several studies reported the use of plerixafor in poorly mobilizing patients, with a success rate ranging from 66 to 85% in small-to medium-sized patient groups. [9][10][11][12] On the basis of these findings, plerixafor is being used more widely in clinical practice. 36,37 Nevertheless, no direct comparison data between plerixafor and ancestim are currently available in poorly mobilizing patients.…”

“…Recently, plerixafor, formerly known as AMD-3100, was shown to be useful in association with G-CSF for a proportion of poorly mobilizing patients. [9][10][11][12] Recombinant human SCF (rhSCF) or ancestim has also been used in this patient subset.…”